Open House Discount Agreement Erythropoietin alfa
Original notice title
Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Erythropoietin alfa, ATC B03XA01
Opportunity Score
Why this score?
Opportunity
60 / 100
Complexity
20 / 100
Risk factors
No estimated value or volume commitment; actual business may be minimal.
Open house model is not subject to procurement law; legal remedies are via social courts, not procurement chambers.
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications
Overview
Strong opportunityKey Facts
- Framework procurement
- Supplies contract
- 1 lot
- Duration until Aug 2027
- Non-exclusive discount agreement for Erythropoietin alfa (ATC B03XA01) with AOK Bayern
- Supply of pharmaceutical products containing the active substance Erythropoietin alfa
Show full summary
Open house non-exclusive discount agreement for the pharmaceutical product Erythropoietin alfa (ATC B03XA01) with AOK Bayern. All interested pharmaceutical companies meeting eligibility criteria can conclude identical, non-negotiable discount agreements. Contracts run from 1 September 2025 to 31 August 2027, with possible termination. This is not a classic procurement procedure but a non-exclusive open-house model under §130a SGB V. No estimated value is published.
Risks
No estimated value or volume commitment; actual business may be minimal.
Open house model is not subject to procurement law; legal remedies are via social courts, not procurement chambers.
Key Requirements
Eligibility
- Only pharmaceutical companies (pharmazeutische Unternehmen) are eligible to participate
Administrative
- Submission of a signed declaration of reliability (Eigenerklärung zur Zuverlässigkeit)
- Submission of the signed contract including the completed appendix 'Festlegung der vertragsgegenständlichen Arzneimittel'
Requirements may be incomplete.
Award Criteria
Lot 1
Buyer
Location
München, DEU
Website
Buyer profile
Identifier
DE811695320
Activity
Health
Lots (1)
LOT-0001
Open House Discount Agreement Erythropoietin alfa
Single lot covering the active substance Erythropoietin alfa. All interested pharmaceutical companies that meet the eligibility criteria can conclude the same discount agreement. The contract can be concluded at any time during the term, latest by 3 July 2027. Submission must be via the communication area of the dtvp portal (not the offer area) or by post with specific deadlines.
Location
Duration
Category
Award Criteria
Deadline
Award details
Not applicable – open house model, no selection or award criteria. Any eligible company can join.
Value note
Show original TED data
Original lot title
Open house Arzneimittelrabattverträge Erythropoietin alfa, ATC B03XA01
Original TED description
Siehe kurze Beschreibung ACHTUNG: Die Vertragsunterlagen sind zwingend über den Kommunikationsbereich im Vergabeportal www.dtvp.de einzureichen und keinesfalls über den Angebotsbereich! BITTE BEACHTEN SIE: Die FRIST für einen Vertragsschluss zum nächsten Monatsersten endet jeweils am DRITTEN des Vormonats.
Procurement Details
- Publication date
- 13 Jul 2025
- Languages
- German
Reference metadata
- Legal basis
- 32014L0024
Reference IDs
- Tender ID
- 458024-2025
Documents (2)
Similar tenders
Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)
Denmark – Pharmaceutical products – Amgros 2027 1.1170.a
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)
Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta
Opportunity Score
Why this score?
Opportunity
60 / 100
Complexity
20 / 100
Risk factors
No estimated value or volume commitment; actual business may be minimal.
Open house model is not subject to procurement law; legal remedies are via social courts, not procurement chambers.
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications